The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Isa-VCd followed by isa + len maintenance in newly diagnosed myeloma with severe renal impairment
Evangelos Terpos, MD, PhD, University of Athens School of Medicine, Athens, Greece, briefly discusses the results of a Phase II study (NCT05147493) evaluating the efficacy of isatuximab in combination with bortezomib, cyclophosphamide, and dexamethasone (Isa-VCd), followed by isatuximab and lenalidomide (len) maintenance in newly diagnosed patients with multiple myeloma (MM) and severe renal impairment. Dr Terpos highlights the study’s promising outcomes, including a high response rate and a median progression-free survival (PFS) that exceeds previous literature for this patient population. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
I think this is a very interesting study because this is a study for renal impaired patients again with creatinine clearance below 30 or under dialysis. The study schema included isatuximab with Velcade (bortezomib), cyclophosphamide and dexamethasone initially and then when the patients have a renal response, then the patients have maintained with isatuximab plus lenalidomide...
I think this is a very interesting study because this is a study for renal impaired patients again with creatinine clearance below 30 or under dialysis. The study schema included isatuximab with Velcade (bortezomib), cyclophosphamide and dexamethasone initially and then when the patients have a renal response, then the patients have maintained with isatuximab plus lenalidomide. So the study has now completed the recruitment of 51 patients and we present here the data of these 51 patients that were, I think to my opinion, extremely good with very high response rate and a median PFS that is much higher than what has been presented in the literature for this specific cohort of patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Amgen: Honoraria, Other: Travel expenses, Research Funding; AstraZeneca: Honoraria, Other: Travel expenses; BMS: Honoraria; EUSA Pharma: Honoraria, Other: Travel expenses; Janssen: Honoraria, Research Funding; GSK: Honoraria, Research Funding; Menarini/Stemline: Honoraria; Pfizer: Honoraria; Sanofi: Honoraria, Other: Travel expenses, Research Funding; Takeda: Honoraria, Other: Travel expenses, Research Funding; Novartis: Honoraria; Antengene: Honoraria, Research Funding; Swixx: Honoraria.
